Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
about
Optimizing mouse models for precision cancer prevention.Topical oral cavity chemoprophylaxis using isotretinoin rinse: A 15-year experience.Transforming Cancer Prevention through Precision Medicine and Immune-oncology.The Conundrum of Genetic "Drivers" in Benign Conditions.Leveraging premalignant biology for immune-based cancer prevention.A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).Genomic approaches to accelerate cancer interception.Cancer Prevention: Lessons Learned and Future Directions.Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer.STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials.PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?
P2860
Q33919192-8A236502-C983-4FA2-9F99-F3391F352A30Q36230020-E567A4C2-957D-4467-A205-0BDDC724E803Q37114360-8BDE7205-F8CB-4284-8A18-670CE7D50E05Q37245787-EB4709F8-0BE1-4076-991A-70D646E5D041Q37304964-3E224BAF-8726-4A10-9609-4588693B73F8Q37669978-58926C99-AF61-4274-9E9F-4247B10D192BQ38635035-D64F6178-470D-4E4F-86C0-90E68B3DFA3EQ38645642-ED6889F4-74C3-486F-960F-4DDC67D519A1Q38651767-F1562E54-0EA7-4C7E-9A73-D24B75AADBA1Q38652183-4DB00D5C-3611-497B-BCEC-7DD092A6F58CQ38850128-65848A4C-5721-45CA-BB59-EFE7A1E26480Q39037941-9E468B1D-BAC3-4941-84D3-A0D33C0C7442Q39398234-A0B024B6-0DD1-422F-99E2-44193DAAEE1EQ42385533-CD5556A1-D5FE-4A68-B394-64F28C8F38E0Q46096667-19C19ABE-DA20-4F71-AB43-D3175B8AE02BQ47849021-D77C3BA1-689F-40B9-96C1-9CAB0190A3E8Q52607160-A84C91DE-D467-4C1C-A16A-2D0E67CF731FQ57821380-77F76F57-1078-40EA-A13D-F8A040C23474
P2860
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Erlotinib and the Risk of Oral ...... OC) Randomized Clinical Trial.
@ast
Erlotinib and the Risk of Oral ...... OC) Randomized Clinical Trial.
@en
type
label
Erlotinib and the Risk of Oral ...... OC) Randomized Clinical Trial.
@ast
Erlotinib and the Risk of Oral ...... OC) Randomized Clinical Trial.
@en
prefLabel
Erlotinib and the Risk of Oral ...... OC) Randomized Clinical Trial.
@ast
Erlotinib and the Risk of Oral ...... OC) Randomized Clinical Trial.
@en
P2093
P2860
P50
P1433
P1476
Erlotinib and the Risk of Oral ...... POC) Randomized Clinical Trial
@en
P2093
Adel El-Naggar
Dong M Shin
Edward S Kim
Elizabeth A Blair
Ezra E W Cohen
Heather Y Lin
Ignacio I Wistuba
J Jack Lee
Jack W Martin
Jay O Boyle
P2860
P304
P356
10.1001/JAMAONCOL.2015.4364
P577
2016-02-01T00:00:00Z